| Imjudo (tremelimumab) / AstraZeneca, Pfizer |
2019-002767-98: A study of immunotherapy combined with regular treatment for liver cancer |
|
|
| Not yet recruiting | 4 | 13 | Europe | IMFINZI, Tremelimumab, Concentrate for solution for infusion, Solution for infusion, IMFINZI | University College Dublin, AstraZeneca | Patients with Hepatocellular Carcinoma, Liver Cancer, Diseases [C] - Cancer [C04] | | | | |
ARCTIC, NCT02352948 / 2014-000338-46: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer |
|
|
| Completed | 3 | 597 | Europe, Canada, Japan, US, RoW | MEDI4736 (durvalumab), Vinorelbine, Gemcitabine, Erlotinib, MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4), tremelimumab (anti-CTLA4) | AstraZeneca | Non - Small Cell Lung Cancer NSCLC | 02/18 | 08/23 | | |
|
|
|
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 1118 | Europe, Canada, Japan, US, RoW | MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab | AstraZeneca | Non-Small-Cell Lung Carcinoma NSCLC | 10/18 | 12/24 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 1126 | Europe, Canada, Japan, US, RoW | MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine | AstraZeneca | Urothelial Cancer | 01/20 | 12/24 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 987 | Europe, Japan, US, RoW | Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide | AstraZeneca | Small Cell Lung Carcinoma Extensive Disease | 01/20 | 12/24 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 3 | 953 | Europe, Japan, US, RoW | Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin | AstraZeneca | Non Small Cell Lung Carcinoma NSCLC | 09/20 | 12/24 | | |
|
| Active, not recruiting | 3 | 1186 | Europe, Japan, US, RoW | Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin | AstraZeneca | Non Small Cell Lung Cancer NSCLC | 03/21 | 12/26 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 1324 | Europe, Canada, Japan, US, RoW | Durvalumab, MEDI4736, Tremelimumab (Regimen 1), Tremelimumab (Regimen 2), Sorafenib, Durvalumab (Regimen 1), Durvalumab (Regimen 2) | AstraZeneca | Hepatocellular Carcinoma | 08/21 | 08/26 | | |
|
|
|
|
|
|
|
2020-005452-38: Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplatin or Who Refuse Cisplatin |
|
|
| Not yet recruiting | 3 | 830 | Europe | Durvalumab, Tremelimumab, Enfortumab vedotin, MEDI4736, EV, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI, Padcev | AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB | Documented muscle-invasive urothelial carcinoma (UC) of the bladder incisplatin ineligible patients or Who Refuse Cisplatin, Cancer in thick muscle in the bladder wall, Diseases [C] - Cancer [C04] | | | | |
NILE, NCT03682068 / 2018-001883-48: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer |
|
|
| Active, not recruiting | 3 | 1246 | Europe, Canada, Japan, US, RoW | Durvalumab, MEDI4736, Tremelimumab, Cisplatin + Gemcitabine, Carboplatin + Gemcitabine | AstraZeneca | Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer | 06/25 | 06/25 | | |
|
|
|
|
|
|
|
NCT04585490: Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC |
|
|
| Recruiting | 3 | 48 | US | Durvalumab, Imfinzi, MEDI-4736, MEDI4736, Carboplatin, Carboplat, Carbosol, Carboplatino, cis-diammine(cyclobutane-1,1-dicarboxylato)platinum, Pemetrexed, Alimta, MTA, LY231514, L-glutamic acid, N-(4-(2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), Paclitaxel, Praxel, Cisplatin, platinum diamminodichloride, Abiplatin, Cismaplat, cis-platinum, Platinex, platinum, diaminedichloro-, cis- (8CI), AVENIO ctDNA Surveillance Kit, Tremelimumab, Imjudo, Tremelimumab-actl, Ticilimumab, CP-675, CP-675,206 | Maximilian Diehn, AstraZeneca | Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc | 04/26 | 04/28 | | |
| Recruiting | 3 | 1750 | Europe | Durvalumab, Tremelimumab | University College, London, AstraZeneca, Kidney Cancer UK, Cancer Research UK | Renal Cell Carcinoma | 07/24 | 12/34 | | |
|
ADRIATIC, NCT03703297 / 2018-000867-10: Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy |
|
|
| Active, not recruiting | 3 | 730 | Europe, Canada, Japan, US, RoW | Durvalumab, MEDI4736, Tremelimumab, Placebo | AstraZeneca | Small Cell Lung Cancer | 03/26 | 03/26 | | |
|
|
|
|
TREMENDOUS, NCT05557838: Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma |
|
|
| Recruiting | 3 | 210 | RoW | Durvalumab, MEDI4736, Tremelimumab | AstraZeneca | Hepatocellular Carcinoma | 03/25 | 03/25 | | |
SIERRA, NCT05883644: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 3 | 110 | Europe, Japan, US, RoW | Durvalumab, Tremelimumab | AstraZeneca | Advanced Hepatocellular Carcinoma | 06/25 | 12/25 | | |
VOLGA, NCT04960709: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin |
|
|
| Recruiting | 3 | 677 | Europe, Canada, Japan, US, RoW | Durvalumab, IMFINZI, MEDI4736, Tremelimumab, Enfortumab Vedotin, PADCEV, Radical Cystectomy | AstraZeneca | Muscle Invasive Bladder Cancer | 07/25 | 09/28 | | |
|
|
|
|
| Recruiting | 3 | 725 | Europe, Canada, Japan, US, RoW | Tremelimumab, MEDI1123, Durvalumab, MEDI4736, Transarterial Chemoembolization (TACE), DEB-TACE and cTACE, Lenvatinib, Lenvima | AstraZeneca | Hepatocellular Carcinoma | 12/25 | 02/27 | | |
|
|
|
TRITON, NCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients |
|
|
| Recruiting | 3 | 280 | US | Durvalumab, Tremelimumab, Pemetrexed, Background Platinum-based Chemotherapy, Pembrolizumab, Carboplatin, Cisplatin | AstraZeneca | Carcinoma, Non-Small-Cell Lung | 08/27 | 03/31 | | |
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2/3 | 660 | Europe, US, RoW | Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab | AbbVie | Hepatocellular Carcinoma | 09/30 | 09/30 | | |
| Active, not recruiting | 2 | 571 | Europe, Canada, US, RoW | Tremelimumab, Placebo | MedImmune LLC | Unresectable Pleural or Peritoneal Malignant Mesothelioma | 01/16 | 04/25 | | |
|
|
|
|
|
|
2005-005660-86: A Phase II, open label, single arm study to evaluate Ticilimumab in Advanced Gastric/Oesophageal Adenocarcinoma |
|
|
| Ongoing | 2 | | Europe | Ticilimumab, CP-675, 206, | Christie Hospital NHS Trust | Advanced Gastric/Oesophageal Adenocarcinoma | | | | |
2016-001688-35: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumors Studio in aperto, randomizzato, di fase 2 con l¿anticorpo anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, da solo o in combinazione con Tremelimumab, in pazienti con neoplasie germinali avanzate e ricadute alla chemioterapia |
|
|
| Ongoing | 2 | 120 | Europe | MEDI4736, Tremelimumab, MEDI4736, MEDI1123, Solution for infusion, Concentrate for solution for infusion | FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI", Astra Zeneca | Advanced and relapsed germ cell tumors Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Germ cell Tumor Neoplasie germinali in fase metastatica ricadute o in progressione dopo trattamento chemioterapico di seconda o terza linea., Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 18 | RoW | Durvalumab,Tremelimumab, Experimental group | Seoul National University Hospital, Korean Cancer Study Group | HNSCC, Head and Neck Neoplasms | 02/19 | 06/21 | | |
| Completed | 2 | 64 | Europe, US, RoW | Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy | AstraZeneca | Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma | 02/18 | 03/23 | | |
|
2017-001664-37: A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLC Studio randomizzato di fase 2 di confronto tra immunoterapia e chemioterapia nel trattamento del paziente anziano |
|
|
| Ongoing | 2 | 240 | Europe | CARBOPLATINO, Durvalumab, Tremelimumab, Gemcitabina, Pemetrexed, [CARBOPLATINO], [Durvalumab], [Tremelimumab], [Gemcitabina], [Pemetrexed], Concentrate for solution for infusion, Solution for infusion, CARBOPLATINO SANDOZ GMBH - 10MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 60ML, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 15 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A. | patients with advanced NSCLC pazienti con NSCLC avanzato, patients with advanced non-small cell lung cancer pazienti con tumore del polmone non a piccole cellule avanzato, Diseases [C] - Cancer [C04] | | | | |
2017-004213-24: A RANDOMIZED TRIAL OF DURVALUMAB AND TREMELIMUMAB ¿ PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK, METASTATIC (STAGE IV) SQUAMOUS OR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) Studio randomizzato di Duravalumab e Tremelimumab ¿ Chemioterapia a base di platino in pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso |
|
|
| Not yet recruiting | 2 | 300 | Europe | Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Durvalumab, Tremelimumab, Gemcitabina, CARBOPLATINO, Pemetrexed, Solution for infusion, Concentrate for solution for infusion, GEMCITABINA ACCORD HEALTHCARE - 1 G POLVERE PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 50 ML, CARBOPLATINO AHCL - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 45 ML, ALIMTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO(VETRO) 1 FLACONCINO | ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, Canadian Cancer Trials Group (CCTG) | Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Patients with high-risk, metastatic (Stage IV) squamous or non-squamous NSCLC. Pazienti affetti da carcinoma del polmone non a piccole cellule, metastatico, ad istotipo squamoso o non squamoso., Diseases [C] - Cancer [C04] | | | | |
2016-003175-22: Trial with immunotherapie for patients with locally advanced head and neck cancer Studie zur Immuntherapie bei Patienten mit lokal fortgeschrittenen Tumoren des Kopf-Hals Bereichs |
|
|
| Ongoing | 2 | 120 | Europe | Durvalumab, Tremelimumab, MEDI4736, Solution for infusion | Charite Universitätsmedizin Berlin, Charité Comprehensive Cancer Center, AstraZeneca GmbH | NON-RESECTABLE LOCALLY ADVANCED HPV NEGATIVE HNSCC, locally advanced head and neck cancer Fortgeschrittene Kopf-Hals Tumoren, Diseases [C] - Cancer [C04] | | | | |
2017-000577-36: DUTRELASCO trial (DUrvalumab with or without Tremelimumab in REsectable Locally Advanced Squamous cell Carcinoma of the Oral cavity) |
|
|
| Not yet recruiting | 2 | 20 | Europe | Tremelimumab, Durvalumab (Medi 4736), Medi 4736, Solution for infusion, Durvalumab (Medi 4736) | University Hospitals Leuven, University Hospitals Leuven, Astra Zeneca | resectable, locally advanced squamous cell carcinoma of the oral cavity, resectable, locally advanced squamous cell carcinoma of the oral cavity, Diseases [C] - Cancer [C04] | | | | |
2017-003226-33: Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC |
|
|
| Ongoing | 2 | 120 | Europe | Durvalumab, Tremelimumab, MEDI4736, MEDI1 123, Concentrate for solution for infusion | Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Jürgen Schüttler, Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg | Locally advanced head and neck squamous cell carcinoma (HNSCC), Head and neck cancer, Diseases [C] - Cancer [C04] | | | | |
2017-003159-44: Durvalumab plus tremelimumab and radiotherapy for localized muscle invasivebladder cancer treatment Durvalumab más tremelimumab y radioterapia concomitante para el tratamiento del carcinoma de vejiga músculo-invasivo localizado |
|
|
| Ongoing | 2 | 32 | Europe | Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion | Spanish Oncology Genitourinary Group, AstraZeneca | Localized muscle invasive bladder cancer Carcinoma de vejiga músculo-invasivo localizado, Invasive bladder cancer Cáncer invasivo de vejiga, Diseases [C] - Cancer [C04] | | | | |
ACTRN12617001468314: Durvalumab and Tremelimumab +/- Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 2 | 80 | | | NHMRC Clinical Trials Centre, Canadian Cancer Trials Group | Lung Cancer Metastatic | | | | |
2018-002014-13: Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancer Évaluation de l'efficacité d'un traitement combiné immunothérapie + chimiothérapie pour traiter les patients atteints d'un cancer de l'estomac. |
|
|
| Not yet recruiting | 2 | 94 | Europe | MEDI4736, tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion | Fédération Francophone de Cancérologie Digestive, Astra Zeneca | Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Advanced gastric or gastro-oesophageal junction adenocarcinoma Adénocarcinome gastrique ou de la jonction oeso-gastrique avancé, Diseases [C] - Cancer [C04] | | | | |
2018-003115-21: A phase II trIal for combination therapy with durvaLumab anD tremelimumAb in patients with metastatic solid tumors |
|
|
| Not yet recruiting | 2 | 108 | Europe | durvalumab, Tremelimumab, MEDI4736, Solution for infusion | Gustave Roussy, AstraZeneca | Metastatic colorectal adenocarcinoma (without microsatellite instability (not MSI)), triple negative breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and human papilloma virus (HPV) negative head and neck squamous cell carcinoma with detection of ≥ 5 somatic mutations per megabase measured by whole exome sequencing in a tumor sample of the patient, Metastatic colorectal adenocarcinoma, breast cancer, prostate adenocarcinoma, stomach and esophageal gastric junction adenocarcinoma and HPV negative head and neck squamous cell carcinoma, Diseases [C] - Cancer [C04] | | | | |
2017-003780-35: Phase II Study: Second line therapy in patients with non small cell lung cancer (NSCLC) with Durvalumab plus Tremelimumab after platinum based chemotherapie compared with platinum based chemotherapy alone Phase II Studie: Zweitlinientherapie in Patienten mit nicht-kleinzelligem Lungenkarzinom (NSCLC) mit Durvalumab plus Tremelimumab nach Platinum-basierter Chemotherapie verglichen mit alleiniger Platinum-basierter Chemotherapie |
|
|
| Not yet recruiting | 2 | 196 | Europe | Durvalumab, Tremelimumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Gemcitabine, MEDI4736, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for infusion | AIO-Studien-gGmbH, AstraZeneca GmbH | Non-small cell lung cancer stage IV Nicht-kleinzelliges Bronchialkarzinom Stadium IV, Lungcancer Lungenkrebs, Diseases [C] - Cancer [C04] | | | | |
2018-002971-17: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by Durvalumab and Tremelimumab combined with Olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after Olaparib treatment Evaluation de l'efficacité d’une double immunothérapie par Durvalumab et Tremelimumab associée à un traitement par Olaparib chez des patients atteints d’un cancer solide porteurs d’une mutation d’un gène de la recombinaison homologue, en réponse ou stables après 8 semaines de traitement par Olaparib. |
|
|
| Not yet recruiting | 2 | 270 | Europe | OLAPARIB, DURVALUMAB, TREMELIMUMAB, AZD2281, MEDI4736, MEDI1123, Coated tablet, Concentrate for solution for infusion, Lynparza 100 mg film-coated Tablet | Centre Georges-François Leclerc, AstraZeneca, Centre Georges-François Leclerc | Patients with the following solid malignancy: • Metastatic breast cancer • Metastatic prostate cancer • Metastatic lung cancer • Metastatic head and neck • Metastatic endometrial cancer • Metastatic clear cell renal cancer • Metastatic pancreatic cancer • Metastatic ovarian cancer • Metastatic urothelial carcinoma Patients atteints d’une tumeur maligne parmi les suivantes : - Cancer du sein métastatique - Cancer de la prostate métastatique - Cancer du poumon métastatique - Cancer de l’endomètre métastatique - Cancer rénal à cellules claires métastatique - Cancer de la tête et du coup (ORL) métastatique - Cancer du pancréas métastatique - Cancer de l’ovaire localement avancé ou métastatique - Carcinome urothélial métastatique, Patient with the following metastatic solid malignancy of breast , prostate , lung , head and neck, endometrial, clear cell renal, pancreatic, ovarian or urothelial . Patient atteint d’une tumeur maligne métastatique du sein, de la prostate, du poumon, de l’endomètre, rénal à cellules claires, de la tête et du coup (ORL), du pancréas, de l’ovaire ou urothéliale., Diseases [C] - Cancer [C04] | | | | |
2019-000308-13: Randomized Phase II study of chemotherapy (cisplatin) plus radiotherapy (RT) versus immunotherapy durvalumab or immunotherapy, durvalumab and tremelimumab, given with and/or after RT in patients with advanced cancer of the oropharynx that contains the human papilloma virus |
|
|
| Not yet recruiting | 2 | 180 | Europe | Durvalumab, Cisplatin, MEDI4736, Concentrate for solution for infusion | European Organisation for Research and Treatment of Cancer (EORTC), European Organisation for Research and Treatment of Cancer (EORTC), Canadian Cancer Trials Group (CCTG), AstraZeneca | Oropharyngeal Squamous Cell Carcinoma, Cancer of the Head and Neck, Diseases [C] - Cancer [C04] | | | | |
2018-004778-81: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care |
|
|
| Not yet recruiting | 2 | 50 | Europe | Durvalumab, Tremelimumab, Solution for infusion, IMFINZI | Institut für Klinische Krebsforschung IKF GmbH, AstraZeneca GmbH, BTG International Ltd. | Intrahepatic Biliary Tract Carcinoma, Intrahepatic Biliary Tract Cancer, Diseases [C] - Cancer [C04] | | | | |
ACTRN12616001019493: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum: durvalumab plus tremelimumab |
|
|
| Completed | 2 | 112 | | | University of Sydney, Office for Health and Medical Research | Cancer | | | | |
| Completed | 2 | 123 | Europe | Durvalumab, MEDI4736, Tremelimumab, CP-675,206 | Grupo Espanol de Tumores Neuroendocrinos | Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung | 11/19 | 05/22 | | |
2018-002852-34: Durvalumab and Tremelimumab with microwave tumor ablation for unresectable locally advanced pancreatic cancer. |
|
|
| Not yet recruiting | 2 | 20 | Europe | Tremelimumab, Durvalumab (Medi4736), MEDI1123, MEDI4736, Solution for infusion, Durvalumab | UZLeuven, AstraZeneca | Unresectable Locally Advanced Non Metastatic Pancreatic Cancer, Pancreatic Cancer, Diseases [C] - Cancer [C04] | | | | |
2018-001066-42: Durvalumab plus tremelimumab for progressive, refractory advanced thyroid carcinoma Durvalumab más tremelimumab para el carcinoma tiroideo avanzado, resistente al tratamiento y progresivo |
|
|
| Not yet recruiting | 2 | 84 | Europe | Durvalumab, Tremelimumab, MEDI4736, Tremelimumab, Solution for infusion, IMFINZI | Spanish Group of Neuroendocrine Tumors (GETNE), AstraZeneca | Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary,follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC).Advanced medullary thyroid carcinoma (MTC)Advanced anaplastic thyroid cancer (ATC) Carcinoma de tiroides diferenciado, avanzado, refractario al yodo radiactivo, incluyendo carcinoma tiroideo papilar, folicular, de células de Hürthle y poco diferenciado (CDT).Carcinoma medular de tiroides (CMT) avanzado.Cáncer anaplásico de tiroides (CAT) avanzado., Thyroid cancer Cáncer de tiroides, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 301 | Canada, RoW | Durvalumab, Tremelimumab, Platinum-Based Drug | Canadian Cancer Trials Group, AstraZeneca, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, National Health and Medical Research Council, Australia | Lung Cancer Metastatic | 02/20 | 12/24 | | |
NCT03046862: Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 31 | RoW | Durvalumab, MEDI4736, Tremelimumab, Gemcitabine, Cisplatin | Seoul National University Hospital | Biliary Tract Neoplasms | 05/20 | 12/24 | | |
2018-003048-22: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition Eine Phase II Studie zur Evaluation der Sicherheit und Wirksamkeit von Durvalumab in Kombination mit der standard neoadjuvanten Therapie sowie zur Evaluation von Durvalumab +/- Tremelimumab bei Patienten mit lokal fortgeschrittenem Adenokarzinom des Ösophagus und zusätzlich Evaluation von Biomarkern, die eine Ansprechen auf Immuncheckpoint Inhibitoren vorhersagen könnten |
|
|
| Not yet recruiting | 2 | 56 | Europe | Durvalumab, Tremelimumab, Solution for injection, Imfinzi® | Universität zu Köln, AstraZeneca Ab | locally advanced esophageal adenocarcinoma lokal fortgeschrittenes Adenokarzinom des Ösophagus, cancer of the esophagus lokal fortgeschrittenes Adenokarzinom der Speiseröhre, Diseases [C] - Cancer [C04] | | | | |
BALTIC, NCT02937818 / 2016-001202-42: A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer |
|
|
| Completed | 2 | 72 | Europe, RoW | Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib | AstraZeneca | Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma | 06/20 | 11/23 | | |
|
CCTG PA.7, NCT02879318: Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 180 | Canada | Gemcitabine, Nab-paclitaxel, Durvalumab, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Pancreatic Adenocarcinoma | 08/20 | 12/24 | | |
2019-004597-26: A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage HCC - IMMUWIN Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Y-90 SIRT bei Patienten mit Leberzellkarzinom im Zwischenstadium - IMMUWIN |
|
|
| Not yet recruiting | 2 | 54 | Europe | Durvalumab, Tremelimumab, Solution for infusion, IMFINZI | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH | Intermediate stage hepatocellular carcinoma (HCC), Intermediate stage hepatocellular carcinoma (HCC), Diseases [C] - Cancer [C04] | | | | |
SOGUG, NCT03702179 / 2017-003159-44: Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach |
|
|
| Active, not recruiting | 2 | 32 | Europe | Durvalumab, MEDI4736, Tremelimumab, Radiotherapy | Spanish Oncology Genito-Urinary Group, AstraZeneca, MFAR | Invasive Bladder Cancer | 09/20 | 12/22 | | |
| Active, not recruiting | 2 | 433 | Europe, Japan, US, RoW | Tremelimumab, Durvalumab, MEDI4736, Bevacizumab | MedImmune LLC | Hepatocellular Carcinoma | 11/20 | 03/25 | | |
|
2020-003440-92: Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability. Studio con la combinazione di due farmaci immunoterapici come terapia prima della chirurgia o come terapia definitiva in pazienti con tumore gastrico o della giunzione gastro-esofagea operabile con instabilità dei microsatelliti. |
|
|
| Not yet recruiting | 2 | 31 | Europe | Durvalumab, Tremelimumab, [MEDI4736], [MEDI1123], Concentrate for solution for infusion | G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST, Fondazione GONO, AstraZeneca S.p.A. | The disease under clinical investigation is represented by resectable gastric or gastroesophageal junction (Siewert II-III) adenocarcinoma staged as cT = 2, any cN, or any cT, cN1-3 (TNM classification 8th edition), without distant metastases (cM0).The study requires central confirmation of tumor molecular status of microsatellite instability and dMMR by both immunohistochemistry and multiplex polymerase chain reaction, and EBV-negative status by silver-in situ hybridization. La malattia oggetto di studio clinico è costituita dall'adenocarcinoma gastrico o della giunzione gastroesofagea (Siewert II-III) resecabile, stadiato clinicamente secondo la classificazione TNM (8° edizione) come cT = 2, ogni cN, oppure ogni cT, cN1-3, senza evidenza di metastasi a distanza (cM0). E' necessaria conferma centralizzata di instabilità microsatellitare mediante immunoistochimica e reazione polimerasica a catena, e status EBV-negativo mediante ibridizzazione in situ argentica., Cancer in the stomach or in the junction between the stomach and the oesophagus, without metastases in other organs and surgically resectable, with microsatellite instability and no EBV infection. Tumore nello stomaco o nella giunzione tra stomaco ed esofago, senza metastasi in altri organi e asportabile chirurgicamente, con instabilità dei microsatelliti e assenza di infezione da EBV., Diseases [C] - Cancer [C04] | | | | |
16-C-0135, NCT02821754: A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) |
|
|
| Completed | 2 | 54 | US | Durvalumab, Imfinzi, Tremelimumab, Ticilimumab, Trans-arterial Catheter Chemoembolization (TACE), TACE, Radiofrequency Ablation (RFA), RFA, Cryoablation, Cryosurgery | National Cancer Institute (NCI) | Biliary Tract Neoplasms, Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma, Bile Duct Cancer | 02/21 | 12/22 | | |
| Completed | 2 | 101 | Europe | Durvalumab, Tremelimumab, Cisplatin-based neoadjuvant chemotherapy, Standard of care (SoC) | Fundacion CRIS de Investigación para Vencer el Cáncer, AstraZeneca, Apices Soluciones S.L. | Bladder Cancer | 04/21 | 04/23 | | |
NCT03377400: Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer |
|
|
| Active, not recruiting | 2 | 40 | RoW | Durvalumab, tremelimumab, 5FU, Cisplatin | Samsung Medical Center | Esophageal Squamous Cell Carcinoma | 06/21 | 12/21 | | |
NCT03450967: Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC |
|
|
| Active, not recruiting | 2 | 31 | RoW | Durvalumab Plus Tremelimumab | Samsung Medical Center | Head and Neck Squamous Cell Carcinoma | 06/21 | 03/22 | | |
ACTRN12618000109202: A Phase II Study of Durvalumab and Tremelimumab in combination with Neoadjuvant Carboplatin and Paclitaxel in newly diagnosed women with advanced high grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers “iPRIME”. |
|
|
| Completed | 2 | 75 | | | Australia New Zealand Gynaecological Oncology Group (ANZGOG), Australia New Zealand Gynaecological Oncology Group (ANZGOG) | Ovarian cancer, Fallopian tube cancer, Peritoneal cancer | | | | |
NRG-GY021, NCT04034927: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer |
|
|
| Active, not recruiting | 2 | 61 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl | National Cancer Institute (NCI), NRG Oncology | Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma | 07/21 | 09/25 | | |
NCT02953457: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation |
|
|
| Completed | 2 | 40 | US | Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Olaparib, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Roswell Park Cancer Institute, AstraZeneca | BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma | 09/21 | 08/24 | | |
| Completed | 2 | 120 | Europe | Durvalumab + Tremelimumab + RT | University of Erlangen-Nürnberg Medical School | Locally Advanced Head and Neck Squamous Cell Carcinoma | 09/21 | 02/24 | | |
2020-003925-42: Study on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer |
|
|
| Not yet recruiting | 2 | 84 | Europe | Tremelimumab, Durvalumab, TheraSphere, Solution for infusion, Implant, TheraSphere | Clinics of Munich University LMU, Astra Zeneca, Boston Scientific | Patients with hepatocellular cancer, not amenable to curative surgical or ablation treatment., tumor of the liver which cannot be removed by surgery or other ablation techniques, Diseases [C] - Cancer [C04] | | | | |
| Active, not recruiting | 2 | 9 | Canada, US | Durvalumab, [MEDI4736], Tremelimumab, [CP-675 206], Thoracic Radiation, lobectomy, Standard of care adjuvant chemotherapy | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca | Non-Small Cell Lung Cancer | 11/21 | 05/25 | | |
NCT02788773: Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer |
|
|
| Active, not recruiting | 2 | 52 | Canada | Durvalumab, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Prostate Cancer | 11/21 | 12/24 | | |
NCT03557918: Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer |
|
|
| Completed | 2 | 26 | US | Tremelimumab | Matthew Galsky, AstraZeneca | Urothelial Carcinoma | 12/21 | 06/23 | | |
2021-002389-41: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit Capecitabin oder ohne Capecitabin in der ADJUvanten Situation bei Gallengangskrebs |
|
|
| Ongoing | 2 | 40 | Europe | Durvalumab, Tremelimumab, Capecitabine, Solution for infusion, Film-coated tablet, IMFINZI | Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, AstraZeneca GmbH | biliary tract cancer, biliary tract cancer, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 60 | Europe | Durvalumab, Tremelimumab | Vall d'Hebron Institute of Oncology | Colorectal Cancer, Endometrial Cancer | 09/25 | 12/25 | | |
| Completed | 2 | 128 | Europe | Durvalumab, Gemcitabine, Cisplatin, Tremelimumab | AIO-Studien-gGmbH, AstraZeneca | Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable, Gallbladder Carcinoma Non-Resectable | 03/22 | 03/22 | | |
|
PRODIGE 59 - DURIGAST, NCT03959293: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Active, not recruiting | 2 | 107 | Europe | Durvalumab, Tremelimumab, FOLFIRI Protocol | Federation Francophone de Cancerologie Digestive, AstraZeneca | Gastric Adenocarcinoma, Gastric Cancer | 03/22 | 11/24 | | |
2021-004061-13: Durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors Tratamiento con durvalumab (MEDI4736) con o sin tremelimumab en tumores colorrectales y endometriales con MSS y MSI |
|
|
| Not yet recruiting | 2 | 60 | Europe | Tremelimumab, Durvalumab, Solution for infusion, Concentrate for solution for infusion | VHIO Vall d’Hebron Institute of Oncology, Astra Zeneca | MSS and MSI colorectal and endometrial tumors Tumores colorrectales y endometriales con MSS y MSI, MSS and MSI colorectal and endometrial tumors Tumores colorrectales y endometriales con MSS y MSI, Diseases [C] - Cancer [C04] | | | | |
NCT02879162: Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours |
|
|
| Active, not recruiting | 2 | 140 | Canada | Durvalumab, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Advanced Rare Tumours | 06/22 | 12/22 | | |
2021-001907-33: A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with TheraSphere alone versus receiving radiation therapy with TheraSphere followed by immunotherapy (durvalumab and tremelimumab treatment) Estudio clínico para evaluar la seguridad y la eficacia de los sujetos con carcinoma hepatocelular (CHC) que reciben radioterapia con TheraSphere sola frente a los que reciben radioterapia con TheraSphere seguida de inmunoterapia (tratamiento con durvalumab y tremelimumab). |
|
|
| Not yet recruiting | 2 | 150 | Europe | Durvalumab, Tremelimumab, MEDI4736, MEDI1123, Concentrate for solution for infusion | Biocompatibles UK Ltd, a wholly owned indirect subsidiary of Boston Scientific Corporation, Boston Scientific Corporation | hepatocellular carcinoma carcinoma hepatocelular, a cancer that starts in the liver un cáncer que comienza en el hígado, Diseases [C] - Cancer [C04] | | | | |
AMBITION, NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer |
|
|
| Recruiting | 2 | 104 | RoW | olaparib+cediranib combination therapy, durvalumab + olaparib combination therapy, durvalumab + chemotherapy treatment, durvalumab + tremelimumab + chemotherapy treatment, durvalumab + tremelimumab + paclitaxel treatment, durvalumab +chemotherapy treatment | Yonsei University, AstraZeneca, Samsung Genomic Institute, Seoul National University Hospital, Samsung Medical Center, Korean Gynecologic Oncology Group | Platinum-resistant Recurrent Ovarian Cancer | 09/22 | 09/22 | | |
TUOAD-RCC, NCT06584435: A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors |
|
|
| Recruiting | 2 | 40 | RoW | Tremelimumab | Tianjin Medical University Second Hospital | High-risk Renal Cell Carcinoma | 12/24 | 03/25 | | |
| Active, not recruiting | 2 | 106 | Europe | Durvalumab, MEDI4736, Tremelimumab, CP-675 | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Advanced Biliary Tract Carcinoma | 07/22 | 12/24 | | |
ACTRN12618001742268: Non small cell lung cancer trial of durvalumab and tremelimumab in advanced epidermal growth factor receptor (EGFR) mutant disease. |
|
|
| Completed | 2 | 100 | | | University of Sydney, Astra Zeneca | EGFR mutant advanced non small cell lung cancer. | | | | |
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
|
|
| Active, not recruiting | 2 | 270 | Europe | olaparib, durvalumab, tremelimumab | Centre Georges Francois Leclerc, AstraZeneca | Immunotherapy | 08/27 | 08/27 | | |
2022-001201-48: Sequential or up-front triple treatment with of durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC) Sequenzielle oder frühzeitige dreifach-Therapie mit Durvalumab, Tremelimumab und Bevacizumab in Patienten mit nicht operierbarem Leberzellkarzinom (HCC)(MONTBLANC) |
|
|
| Not yet recruiting | 2 | 70 | Europe | IMFINZI, Tremelimumab, Aybintio, L01FG01, Concentrate for solution for infusion, IMFINZI, Aybintio | Klinikum der Ludwig-Maximillians-Universität München, Astra Zeneca | non-resectable hepatocellular carcinoma (HCC) nicht-resezierbares Hepatozelluläres Karzinom, non-resectable hepatocellular carcinoma (HCC) nicht-resezierbares Hepatozelluläres Karzinom, Diseases [C] - Cancer [C04] | | | | |
| Completed | 2 | 69 | Europe | Savolitinib, Volitinib, AZD6094, MEDI4736, Durvalumab, Tremelimumab | Queen Mary University of London, Vall d'Hebron Institute of Oncology, AstraZeneca | Renal Clear Cell Carcinoma, Renal Papillary Cell Carcinoma | 07/24 | 07/24 | | |
|
|
ACTRN12620000918921: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 7: Tremelimumab |
|
|
| Completed | 2 | 24 | | | The University of Sydney, Office for Health and Medical Research, Outsmarting Cancer Together - OMICO | cancer | | | | |
2023-000138-13: Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational study. CITATION study Studio multicentrico, interventistico, prospettico, farmacologico su chemio e immunoterapia neo- adiuvanti con durvalumab e tremelimumab nel trattamento preoperatorio del Colangiocarcinoma localmente avanzato: uno studio esploratorio traslazionale. STUDIO CITATION. |
|
|
| Not yet recruiting | 2 | 38 | Europe | Tremelimumab, Gemcitabina, Cisplatino, DURVALUMAB, [Tremelimumab], [Gemcitabina], [Cisplatino], [DURVALUMAB], Concentrate for solution for infusion, IMFINZI - 50 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 10 ML - 1 FLACONCINO | ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A. | Locally advanced cholangiocarcinoma patients Pazienti affetti da CCA localmente avanzato, Locally advanced cholangiocarcinoma patients Pazienti affetti da CCA localmente avanzato, Diseases [C] - Cancer [C04] | | | | |
NCT04221555: Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab | Asan Medical Center | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 04/25 | 04/25 | | |
2021-004411-11: To investigate the efficacy and safety of neoadjuvant (preceding surgical removal) treatment with two cytostatic agents (gemcitabine, cisplatin) in combination with two monoclonal antibodies (durvalumab, tremelimumab) in patients with a specific type of malignant liver cancer. Untersuchung der Wirksamkeit und Sicherheit einer neoadjvanten (der operativen Entfernung vorgelagerten) Behandlung mit zwei Zytostatika (Gemcitabin, Cisplatin) in Kombination mit zwei monoklonalen Antikörpern (Durvalumab, Tremelimumab) bei Patienten mit einer bestimmten Form von bösartigem Leberkrebs |
|
|
| Not yet recruiting | 2 | 31 | Europe | Tremelimumab, Concentrate for solution for infusion, Powder for solution for infusion, IMFINZI | University Hospital Schleswig-Holstein, Campus Lübeck, AstraZeneca GmbH | Intrahepatic cholangiocarcinoma Intrahepatisches Cholangiokarzinom, Cancer that occurs in the parts of the bile ducts that are within the liver Krebs, der in den Teilen der Gallengänge auftritt, die sich innerhalb der Leber befinden, Diseases [C] - Cancer [C04] | | | | |
ILLUMINATE, NCT03994393: Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. |
|
|
| Active, not recruiting | 2 | 100 | RoW | Tremelimumab, Durvalumab | University of Sydney, AstraZeneca, Australasian Lung Cancer Trials Group | EGFR Mutant Advanced Non Small Cell Lung Cancer | 06/23 | 01/24 | | |
DUTHY, NCT03753919: Durvalumab Plus Tremelimumab for the Treatment of Patients with Progressive, Refractory Advanced Thyroid Carcinoma -The Trial |
|
|
| Terminated | 2 | 79 | Europe | Durvalumab, MEDI4736, Tremelimumab | Grupo Espanol de Tumores Neuroendocrinos, MFAR | Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer | 11/24 | 11/24 | | |
NCT04625699: Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment |
|
|
| Withdrawn | 2 | 15 | NA | Durvalumab, MEDI4736, IMFINZI, Tremelimumab, formerly CP-675,206 | Catherine Shu | Nonsmall Cell Lung Cancer | 07/23 | 12/23 | | |
DURTRE-RAD, NCT03624231: Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC |
|
|
| Completed | 2 | 18 | Europe | Durvalumab, MEDI4736, Tremelimumab, Radiotherapy | Ulrich Keilholz, Charite University, Berlin, Germany, AstraZeneca | Squamous Cell Carcinoma of the Head and Neck | 08/23 | 08/23 | | |
| Not yet recruiting | 2 | 30 | Europe | Durvalumab, Tremelimumab, Concentrate for solution for infusion, IMFINZI®, TREMELIMUMAB | Assistance publique - Hôpitaux de Paris, AstraZeneca | Hepatocellular carcinoma (HCC), Hepatocellular carcinoma (HCC), Diseases [C] - Cancer [C04] | | | | |
NCT06341764: Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma |
|
|
| Recruiting | 2 | 38 | Europe | Durvalumab 1120 mg, Durvalumab 1500 mg, Tremelimumab i.v. at 300 mg, Cisplatin (CDDP) 25 mg/mq i.v, Gemcitabine (GEM) 1000 mg/mq i.v. | National Cancer Institute, Naples | Cholangiocarcinoma | 09/25 | 09/25 | | |
NCT03737968: Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients. |
|
|
| Active, not recruiting | 2 | 48 | RoW | Durvalumab, durvalumab + tremelimumab | Yonsei University | Stage II-IVB Operable HNSCC Oral Cavity, Hypopharynx, Oropharynx, Larynx | 10/23 | 10/23 | | |
NCT00378482 / 2008-000989-23: A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. |
|
|
| Completed | 2 | 37 | Europe, US | CP-675,206 (Tremelimumab), anti-CTLA4 human monoclonal antibody | AstraZeneca | Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma, Neoplasms, Patients Who Have/Have Had Melanoma and Other Tumors | 10/23 | 10/23 | | |
NCT02888743: Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 110 | Canada, US | Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP 675, CP 675206, CP-675, CP-675,206, CP-675206, CP675, CP675206, Imjudo, Ticilimumab, Tremelimumab-actl | National Cancer Institute (NCI) | Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7 | 12/23 | 01/25 | | |
NCT03385655: Prostate Cancer Biomarker Enrichment and Treatment Selection |
|
|
| Active, not recruiting | 2 | 200 | Canada | Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib, Durvalumab and Tremelimumab, Carboplatin | Canadian Cancer Trials Group, Canadian Cancer Clinical Trials Network, BC Cancer Foundation | Prostate Cancer | 12/24 | 12/25 | | |
ACTRN12617001325392: BCT 1703 (DIAmOND): Patients with HER2-positive breast cancer that have progressed on prior trastuzumab therapy will be treated with a combination of tremelimumab and durvalumab, in combination with trastuzumab, to evaluate the efficacy of the combination treatment. |
|
|
| Active, not recruiting | 2 | 78 | | | Breast Cancer Trials, Breast Cancer Trials | Advanced HER2-positive breast cancer | | | | |
MILES-5, NCT03975114: A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC |
|
|
| Recruiting | 2 | 460 | Europe | Chemotherapy, Durvalumab, Tremelimumab | National Cancer Institute, Naples, University of Campania "Luigi Vanvitelli", AstraZeneca | Carcinoma, Non-Small-Cell Lung | 12/23 | 06/24 | | |
MIMIPAC, NCT04156087: Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer |
|
|
| Completed | 2 | 12 | Europe | Durvalumab 50 MG/ML, MEDI4736, IMFINZI, Tremelimumab, Gemcitabine, Gemzar, Minimally Invasive Surgical Microwave Ablation (MIS-MWA) | Baki Topal, AstraZeneca | Pancreatic Cancer Non-resectable | 01/24 | 01/24 | | |
NCT03937830: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma |
|
|
| Recruiting | 2 | 72 | US | durvalumab, Doxorubicin-Eluting Beads, TACE, bevacizumab, Tremelimumab | National Cancer Institute (NCI) | Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 12/25 | 12/25 | | |
NCT03638141: CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab |
|
|
| Completed | 2 | 21 | US | Durvalumab, MEDI4736, Tremelimumab (Cohort A dose), CP-675,206, Tremelimumab (Cohort B dose) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca | Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma | 08/24 | 08/24 | | |
NCI-2018-01415, NCT03601455: Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer |
|
|
| Active, not recruiting | 2 | 13 | US | Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Jonsson Comprehensive Cancer Center, AstraZeneca | Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8 | 01/25 | 01/26 | | |
NCT06364007: HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC |
|
|
| Recruiting | 2 | 20 | RoW | HAIC+STRIDE+Len | Sulai Liu | Hepatocellular Carcinoma | 12/25 | 03/26 | | |
| Active, not recruiting | 2 | 56 | Europe | Durvalumab 50 MG/ML, Tremelimumab | University of Cologne, AstraZeneca | Esophageal Adenocarcinoma | 06/24 | 06/24 | | |
NCT04395079: Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies |
|
|
| Active, not recruiting | 2 | 9 | US | Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Internal Radiation Therapy, Brachytherapy, Brachytherapy, NOS, Internal Radiation, Internal Radiation Brachytherapy, Radiation Brachytherapy, Radiation, Internal, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab | Jonsson Comprehensive Cancer Center, AstraZeneca | Metastatic Malignant Female Reproductive System Neoplasm, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Female Reproductive System Neoplasm | 12/25 | 12/26 | | |
CCTG IND.238A, NCT03847649: A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies |
|
|
| Recruiting | 2 | 60 | Canada | Durvalumab, Prednisone, Tremelimumab | Canadian Cancer Trials Group, AstraZeneca | Cancer | 04/30 | 04/31 | | |
